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Abstract
This study investigates the relationship between FDG
uptake as determined by positron emission tomography
(PET) imaging and rates of tumor growth, cellular
GLUT1 transporter density, and the activities of hex-
okinase and glucose-6-phosphatase in a solid tumor
implant model. Five different human colorectal xeno-
grafts of different growth properties were implanted in
athymic rats and evaluated by dynamic 18F-FDG-PET.
The phosphorylating and dephosphorylating activities
of the key glycolytic enzymes, hexokinase and glucose-
6-phosphatase, were measured in these tumor types by
spectrophotometric assays and the expression of
GLUT1 glucose transporter protein was determined by
immunohistochemistry. Correlations among FDG accu-
mulation, hexokinase activity, and tumor doubling time
are reported in these colon xenografts. The results
indicate that the activity of tumor hexokinase may be a
marker of tumor growth rate that can be determined by
18F-FDG-PET imaging. PET scanning may not only be
a useful tool for staging patients for extent of disease,
but may provide important prognostic information
concerning the proliferative rates of malignancies.
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Introduction
It has been long noted that neoplastic tissues have increased
rates of glycolysis [1 ] . The increased utilization of glucose
by tumors has been attributed to both an increased activity of
membrane glucose transporters such as GLUT1 [2–5] , as
well as an increase in rate- limiting enzymes of the glycolytic
pathway including hexokinase [6,7] . This high consumption
of glucose provides energy for cell growth and also provides
precursors for nucleotide and lipid synthesis [8 ] . Using a
fluorinated glucose analog, [18F]2- fluoro-2-deoxy-D-glu-
cose (FDG), positron emission tomography (PET) exploits
these tumor-related cellular changes to provide detection
and staging of a variety of human malignancies [9–13] . Like
glucose, FDG is transported by GLUT1. After phosphoryla-
tion by hexokinase, however, FDG-6-phosphate cannot
proceed along the glycolytic pathway because it is not a
substrate for the next enzyme in the glycolytic pathway,
phosphohexose isomerase. 18F-FDG-6-phosphate is
essentially trapped within the tumor cell and may be imaged
by PET. This imaging technique has moved into the clinical
realm of diagnosis, staging, and treatment planning
[9,14,15] .
Indirect evidence suggests that FDG accumulation may
reflect tumor aggressiveness. There is correlation between
the accumulation of FDG and histological grade in lung, brain,
hepatic, and musculoskeletal neoplasms [9,10,17–19] .
Correlations among tumor FDG accumulation, cell cycle,
Ki -67 indices, and p53 overexpression have also been
reported [16,17,20–22] . This report extends these previous
observations by comparison of 18F-FDG-PET findings with
the growth rates of colorectal tumor implants in an animal
xenograft model and evaluates the biochemical determinants
of FDG uptake.
Materials and Methods
Animals and Tumors
Tumor cells. Five colorectal carcinoma cell lines were used in
this study. HCT8, HT29, and LS174T were obtained from the
American Type Culture Collection (Rockville, MD). C29 and
C85 were isolated and characterized at Memorial Sloan-
Kettering Cancer Center as previously described [23] . C85,
C29, and HCT8 were cultured in RPMI with 10% fetal calf
serum (FCS) supplemented with 5 mM L-glutamine.
LS174T was cultured in RPMI with 10% FCS and non-
essential amino acids and 5 mM L-glutamine. HT29 was
cultured in McCoy’s 5A media with 10% FCS. Cells were
maintained in a 5% CO2 humidified environment at 378C.
Histologically, these cell lines produce tumors that range from
moderate grade (C29, HCT8, and HT29) to moderate/poor
grade (C85 and LS174T) [23] .
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Animal models All experiments were performed under
guidelines approved by the Memorial Sloan-Kettering
Institutional Animal Care and Use Committee. Male
athymic rats (National Cancer Institute, Bethesda, MD)
were used in all animal studies. Five human colorectal
cancer cell lines were used to establish xenografts at two
or three sites at the base of the neck on the anterior chest
wall. This site was selected in order to avoid body areas
with high FDG uptake such as the brain, heart, and
bladder. Tumor cells (2106 in 50 l of culture media)
were injected subcutaneously at each tumor site. In any
individual animal, all xenografts were derived from the
same cell line. Tumor volumes were calculated three times
per week using the formula for a prolate spheroid, 4 /
3( )ab2, with a as the radius of the long axis and b as the
radius of the short axis in millimeters [23] . These
measurements were carefully performed with vernier
calipers. The log10 of the average tumor volume was
plotted against time and tumor doubling time was deter-
mined from the logarithmic growth phase.
PET
Rats were imaged by PET when tumor volume reached
350 mm3 (9.5±1.3 mm diameter) to minimize variations
due to partial volume effect. Region of interest (ROI)
analyses on tumors of these volumes produce reliable
measurements of FDG uptake in experimental models
[24] . Five groups of animals were used, with animals
bearing xenografts from one of the five cell lines (n6 per
group) . Food was removed from the rats 6 hours prior to
injection with FDG and rats weighed approximately 250 g
at the time of scan. The PET scan was performed on a
clinical GE Advance PET scanner (General Electric,
Milwaukee, WI) [25] . Animals were anesthesized with a
single intraperitoneal injection of pentobarbital (50 mg/kg)
and placed in the supine position on the detector ring. The
extremities were extended and restrained by laboratory
tape to a Styrofoam platform. FDG, 3.7 MBq (100 Ci) ,
was administered through the tail vein. Dynamic scans
were acquired within ten 2-minute frames ( from 0 to 20
minutes) and four 5-minute frames ( from 20 to 40
minutes) , initiated at the time of injection of the radio-
tracer. A 6-minute transmission scan was performed using
two Ge-68 rods immediately upon completion of the
dynamic scan. Images were reconstructed using attenu-
ation correction by filtered back projection into a
(128128) matrix by a Hanning filter with an 8.5-mm
cutoff frequency and 4-mm Gaussian smoothing in three
dimensions.
ROIs were drawn according to the methodology of Erdi
et al. [26] . In brief, this is an adaptive thresholding
technique in which regions are manually drawn around the
lesion circumference, but at specific window display setting
on the PET workstation, corresponding to the appropriate
lesion size and contrast. ROIs were drawn around each of
the tumors in the frame for which the tumor showed
maximum radioactivity. Serial changes of maximum tumor
radioactivity (nCi /ml tissue) were determined dynamically
from a sequence of images. Standard uptake value (SUV)
analysis was performed for each tumor from the images
acquired following FDG administration. SUV is defined as
the tumor tissue activity (Ci/ml ) divided by the injected
dose (Ci) per body weight of the rat (g) . The maximum
SUV utilizes the activity per milliliter in the hottest pixel
within a ROI delineating the tumor and yields the highest
measured SUV for the tumor. All SUVs were obtained
from the final 5-minute frame, when tumor uptake had
reached a plateau. Recovery coefficients for the GE
Advance were measured using spheres of several different
diameters (4 to 27 mm) containing known specific
activities of F-18 within a cylindrical Jaszczak phantom.
The entire SUV data were then corrected for partial
volume effects by dividing the specific activity determined
for every tumor ROI with the recovery coefficient for a
sphere of the same equivalent diameter. The SUV is then
given by this partial volume effect corrected lesion activity
per gram divided by the quotient of the injected activity
and the rat weight. In all tumors, FDG uptake was lower
than the liver, brain, heart, and bladder, and for this
reason, the tumors were grown on the anterior chest wall
at the base of the neck to provide adequate contrast for
visualization.
Tissue Excision and Analysis
Separate groups of four to six animals per tumor type
were used to characterize the xenograft enzyme activities
(n=6) , GLUT1 glucose transporter expression (n=4) , and
tumor growth rates (n6) . When tumor volume reached
350 mm3, animals were sacrificed by CO2 inhalation.
Tissues were excised and immediately assayed for
hexokinase and glucose-6-phosphatase or fixed in paraf-
ormaldehyde for immunohistochemical analysis of paraffin
sections.
Enzyme assays Hexokinase (EC 2.7.1.1) and glucose-6-
phosphatase (EC 3.1.3.9) activities were measured in
accordance with the methods of Bergmeyer [27] . Upon
sacrifice, tumors were removed, washed in phosphate-
buffered saline (PBS) , and cut into halves. One portion was
used for determination of hexokinase and the other portion
for determination of glucose-6-phosphatase.
Hexokinase was determined spectrophotometrically by
measuring the reduction rate of nicotinamide adenine
dinucleotide phosphate at 340 nm with glucose-6-phos-
phate dehydrogenase. Tissues were homogenized in 4 vol
of buffer containing 150 mM KCl, 5 mM MgCl2, 5 mM EDTA,
and 5 mM 2-mercaptoethanol. The high-speed super-
natant (100,000g for 30 minutes) was assayed. The
reaction cocktail consisted of 40 mM triethanolamine buffer
(pH 7.6) , 8 mM MgCl2, 0.91 mM  -NADP, 0.64 mM ATP,
1.5 U glucose-6-phosphate dehydrogenase, and 5 mM
glucose. One unit of hexokinase activity catalyzed the
formation of 1 nmol of glucose-6-phosphate per minute in
the presence of 5 mM glucose. Activities are expressed as
units per milligram protein.
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For determination of glucose-6-phosphatase, tissues
were homogenized in 4 vol of a 0.25 M sucrose solution.
Pure tissue homogenates were assayed to determine the
amount of inorganic phosphate liberated per unit time by the
formation of a blue phosphomolybdous complex that is
visible at 700 nm. One unit of activity corresponded to the
formation of 1 nmol of inorganic phosphate liberated per
minute. Enzyme activities were standardized to total protein
content determined according to the methods of Bradford
[28] .
Immunohistochemistry
GLUT1 The polyclonal rabbit antiglucose transporter protein
reactive with GLUT-1 ( rat ) (Alpha Diagnostic, San Antonio,
TX) was raised against synthetic peptide (12-mer) based
on the deduced amino acid sequence of the carboxy
terminus of the rat brain glucose transporter. This antibody
immunoreacts with human and rat tissues expressing the
GLUT1 protein. It was diluted 1:20,000 with PBS (PBS)
containing 2% bovine serum albumin (Sigma, St. Louis,
MO). The bound antibody was visualized by routine avidin /
biotin conjugate immunoperoxidase procedure using the
Vectastain Elite kit (Vector, Burlingame, CA) [29] .
Paraffin sections (8 m thick) were deparaffinized with
histoclear and an ethanol gradient. Sections were washed in
PBS and then quenched in 10% hydrogen peroxide
(Sigma). Antigen retrieval was performed in 0.01 M citric
acid (pH 6) for 15 minutes at high power in a laboratory
microwave. Sections were washed in PBS and then blocked
with avidin, biotin, and then 10% normal goat serum.
Sections were again washed in PBS and then incubated
overnight with the primary antibody at 48C. Finally, perox-
idase activity was demonstrated using 3,30 -diaminobenzi-
dine tetrahydrochloride (DAB) (Sigma) as substrate–
chromogen solution. Sections were lightly counterstained
with Harris hematoxylin, dehydrated in graded ethanol and
then histoclear, and mounted.
To confirm specificity of GLUT1 staining, parallel
sections were stained with GLUT1 antiserum that had been
previously incubated with excess of immunizing peptide
antigen (50 g/ml) . Sections of paraffin-embedded 7.5-
day-old mouse embryos and mouse testis were used as
positive controls.
Immunohistochemical grading The immunoreactivity of
GLUT1 was evaluated by one pathologist blinded to tumor
growth rate, SUV, and enzyme activities. GLUT1 immunos-
taining was quantitated by grading the proportion of viable
cancer cells that were GLUT1-positive [30] . Sections with
cancer cells that positively demonstrated membranous
staining at any frequency and intensity were considered
GLUT-positive.
Statistical Analysis
Differences among groups of measurements were ana-
lyzed using a Student’s t - test. A P value of .05 or less was
considered significant. Least -squares linear regressions
were used to analyze relationships among SUV, hexokinase
activity, and tumor doubling time.
Results
PET
Dynamic PET images were obtained for each animal. The
site of tumor implantation was chosen to ensure that each
tumor was readily distinguished from the surrounding
tissues. Figure 1A and B are representative PET images of
C85 and C29 xenograft -bearing rats obtained during the
40th minute of the scan. Figure 2 shows the mean tissue
time–activity curves for each xenograft. The rate of
accumulation of FDG in all tumors demonstrated a plateau.
By 40 minutes, LS174T xenografts demonstrated the highest
FDG uptake (667±4 nCi /ml tissue, SUV 2.20±0.16) and
the C29 xenograft showed the lowest uptake (259±18 nCi /
ml, SUV 1.27±0.21) . HCT8, C85, and HT29 showed
moderate uptake of FDG (447±36, 487±32, 457±66 nCi /
ml; SUV 1.74±0.22, 1.84±0.26, 1.57±0.34) . These data
are shown in Figure 2 as maximum SUV of each xenograft
plotted against time and in Figure 3 as maximum SUV
calculated at 40 minutes for each xenograft. At 40 minutes,
SUV measurements varied significantly (P<.05) among
xenografts of the various cell lines.
Enzyme Analysis
A summary of enzyme data is provided in Table 1.
Hexokinase activities varied significantly among tumor types
(Table 1) . LS174T xenografts demonstrated the highest
hexokinase activities (25.3±5.6) ; HCT8, C85, and HT29
xenografts demonstrated moderate activities (20.4±3.4,
23.3±2.0, 23.4±6.5) ; and C29 xenografts demonstrated
the lowest activities (13.3±1.7) . A direct correlation
between SUV and levels of hexokinase was found in these
five colorectal xenografts ( r=0.9; Figure 4 ) . No statistical
differences in glucose-6-phosphatase activities were appa-
rent among these colon tumors (Table 1) .
Doubling Time
In vivo tumor volume doubling times ranged from 45
hours (LS174T) to 184 hours (C29) . SUV correlated
directly with in vivo tumor doubling time ( r=0.82; Figure
5 ) . Hexokinase activity in tumor tissues also correlated with
in vivo tumor doubling time ( r=0.83; Figure 5 ) .
Immunohistochemistry
All xenografts showed specific GLUT1 immunostaining of
the plasma membrane in at least 10% of viable cancer cells.
Expression of GLUT1 varied from moderate to intense and
was especially prominent at cell–cell boundaries. In all
cases, this reticulated GLUT1 staining pattern was abolished
by preincubation of the antiserum with GLUT1 peptide. The
highest levels of GLUT1 expression were observed in
clusters of cells within glandular units and in cell layers
bordering necrotic islands. The frequency of GLUT1 immu-
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nostaining was consistent among sections from tumors of
the same cell line and among different sections of the same
tumor within variation of less than 10%. The results for
GLUT1 expression are summarized in Table 1. Sections
from HT29 and HCT8 xenografts stained positively for
GLUT1 at a greater frequency (40% to 80%) than sections
from C29, C85, and LS174T xenografts (10%). There was
no apparent correlation of GLUT1 to either doubling time or
SUV.
Discussion
PET after administration of the glucose analogue, [18F] fluo-
rodeoxyglucose, is a non- invasive imaging modality that has
substantial potential for managing patients with cancer. This
imaging modality exploits the high glucose utilization of
tumor cells for imaging of metastases [31] . For glucose-
avid tumors such as colorectal neoplasms, there is sufficient
evidence that FDG-PET may assist in detection of occult
disease and FDG-PET is currently utilized clinically for
improved staging of patients [32–34] . Unlike other imaging
modalities, PET supplies a quantitative metabolic character-
ization of tissues that may also provide information concern-
ing tumor behavior. The current experiments were therefore
designed to test the hypothesis that FDG-PET character-
istics correlate with tumor proliferative rates and rate- limiting
glycolytic enzyme activity. Using a series of cell lines with
diverse growth rates, results of dynamic 18F-FDG-PET
scanning confirm that tumors may reach characteristic
plateau FDG uptakes that correlate with growth.
FDG studies have been performed on transformed and
malignant tissues in vitro to elucidate the mechanisms of
increased tumor glucose utilization, and yet no consensus
has been reached as to which element in cellular metabolism
is most important for cellular retention and uptake of FDG
[35–38] . Three main factors are thought to be the most
influential on cellular FDG accumulation. FDG is transported
into the cell by glucose transport proteins such as GLUT1
[39] . Once transported into the cell, FDG is phosphorylated
by the glycolytic enzyme hexokinase to become 18F-FDG-
PO4, which is selectively retained within the tumor cell
because of the low membrane permeability of FDG-6-
Figure 3. Comparison of maximum SUVs of five human colorectal xenografts.
Open circles represent individual SUV values and closed circles represent the
mean ( ±SD) for each set of values. Significance differences between groups
of xenografts is indicated by ( * ) .
Figure 1. Cross - sectional PET images of tumor -bearing rats taken 40
minutes following intravenous administration of FDG. Rats are in the supine
position and the level of cross section is at the upper thorax. Xenografts
(arrows ) are located on the superior anterior chest wall at the base of the
neck. Areas of brightness represent regions of greater [ 18F ]FDG concen-
tration. (A ) Rat bearing two representative C85 human colorectal xenografts.
(B ) Rat bearing two representative C29 human colorectal xenografts.
Figure 2. Average time–activity curves of [ 18F ]FDG accumulation in five
human colorectal xenografts. Data points represent then mean ( ±SD ) for
each set of xenografts.
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phosphate [40] . The levels of FDG-PO4 also depend on the
activity of glucose-6-phosphatase, the enzyme which
removes the phosphate from this compound. The current
report demonstrates that tumor cell hexokinase is more
important than glucose-6-phosphatase activity or GLUT1-
mediated transport in influencing the accumulation of FDG in
this in vivo rat xenograft model. Furthermore, this FDG
accumulation as imaged by whole-body PET can be used to
assess tumor growth rate.
The idea that cellular glucose metabolism may correlate
to tumor growth and aggressiveness has been suggested in
past studies. Previous reports have demonstrated a corre-
lation of glucose metabolism with tumor growth rate and with
the loss of histological differentiation in transplantable rat
tumors [41,42] . In addition, the glucose transporter protein
GLUT1 has been documented to be expressed in high levels
in tumor cells [30,43] . Glucose transporter protein expres-
sion is also rapidly induced experimentally by growth factors
such as fibroblast growth factor, platelet -derived growth
factor, or epidermal growth factor [44] . These same factors
have been demonstrated to be local growth factors, trophic
for colorectal cancer growth, and tumor levels of these
growth factors have been found to be prognostic for outcome
[45,46] . In breast cancer, GLUT1 expression has been
correlated to higher grade and proliferative rate of tumors
[43] . In lung cancer, GLUT1 and GLUT3 expression has
been associated with poor survival [30] . Glucose trans-
porter protein expression may therefore be a marker and a
cause of increased tumor aggressiveness. Although faint
expression of a number of the seven identified GLUT
transporters may be observed, it has been established that
GLUT1 is the most highly expressed in colon cancers [5 ]
and small cell lung carcinoma [47] . In the current in vivo
studies, we did not find a correlation of GLUT1 expression to
either tumor growth rates or to FDG accumulation. Whether
other less commonly expressed GLUTs contribute to FDG
transport in this model was not specifically addressed here.
In the tumors examined, hexokinase activity appears to be a
more important determinant of cellular glucose and FDG
metabolism. Whether in tumors of equal hexokinase activity
the GLUT1 expression will distinguish tumors in terms of
behavior cannot be determined from the limited number of
tumors assayed.
In normal tissues, significant glucose-6-phosphatase
activity has been shown to correlate with the rapid clearance
Figure 5. The relationship between tumor doubling time, maximum SUV, and
hexokinase. SUVmax (mean±SEM) for each colorectal xenograft ( open
circles ) , and the activity of hexokinase (mean±SEM) for each colorectal
xenograft ( filled circles ) are both correlated to the tumor doubling time.
Figure 4. Correlation of maximum SUV (mean±SEM) with the activity of
hexokinase (mean±SEM) in five human colorectal xenografts. Each
xenograft is represented by a filled circle.
Table 1. Glycolytic Parameters, Tumor Doubling Times, and SUVmax for Five Human Colorectal Cancer Xenografts.
Xenograft Hexokinase (U /mg ) * G -6 -PASE (U /mg ) * GLUT1 (%) y Doubling Time (hours ) SUVmax
z
C29 13.3±1.7 30.9±1.9 10 184 1.27±0.21 (n=8 )
HCT8 20.4±3.4x,{ 29.9±1.7 80 173 1.74±0.22x,{ (n=8 )
C85 23.3±2.0x 29.5±2.1 10 120 1.84±0.26x,{ (n=8 )
HT29 23.4±6.5x 28.7±1.9 40 110 1.57±0.34x (n=6 )
LS174T 25.3±5.6x 42.7±10.8 10 45 2.20±0.16x (n=6 )
Data are presented as mean±SD.
*Activity of hexokinase and glucose -6 - phosphatase was measured as described in the Materials and Methods section.
yEach value represents the relative percentage of GLUT1 -positive cells per section of tissue.
zMaximum SUV value is the activity per milliliter in the hottest pixel within a ROI delineating the tumor. It is the highest measured SUV for the tumor.
xDifferences between each HCT8, C85, and LS174T xenograft and C29 xenograft were significant (P< .05 ) .
{Differences between each HCT8 and C85 xenograft and LS174T xenograft were significant (P< .05 ) .
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of titrated deoxyglucose [35] . Unlike tissues such as liver or
kidney, glucose-6-phosphatase levels have been found at
low levels in tumors [48,49] . The current study confirmed the
low level of glucose-6-phosphatase activity in colorectal
cancer cells, and found that such activity was not significantly
different among thevarious colon tumors. Thesedata suggest
that neither GLUT1 or glucose-6-phosphatase in colon
tumors plays a rate- limiting role in vivo in regulating the
accumulation of FDG in these cell lines in a rat xenograft
model.
Rather, hexokinase activity demonstrated the greatest
correlation with FDG and tumor behavior in this xenograft
model of colorectal cancer. Hexokinase begins the first step
of the glycolytic cycle and is overexpressed in many tumors
[6,7,50–53] . In fact, of the four hexokinase isozymes ( I, II,
III, and IV) , it appears that type II isoenzymes, and to a lesser
degree type I, are overexpressed in highly glycolytic, rapidly
growing tumors [31] . Concentration of FDG-6-phosphate in
liver and esophageal malignancies has been shown to
correlate with tissue levels of hexokinase [9,11] . The current
study extends these observations in documenting not only
that FDG imaging is most dependent on cellular hexokinase
levels, but that the hexokinase activity and FDG accumu-
lation as imaged by PET reflect tumor proliferative rates.
Some clinical observations are consistent with our current
findings. Glucose metabolic rates as determined by 18F-
FDG PET have been found to parallel changes in tumor size
on repeated computed tomography scans in four patients
with intracranial meningioma [54] . FDG uptake has been
correlated to pathologic grade in a large array of human
malignancies [9,16–20] . There have also been descriptions
of changes in 18F-FDG uptake correlating to change in tumor
histology. In the treatment of testicular cancers with chemo-
therapy, there is often a change in histologic appearance of
the tumor from the more poorly differentiated embryonal
carcinoma to the more well -differentiated mature teratoma.
Such a shift in histology has been seen coincident with a
decrease in FDG uptake by PET scanning [55] . Similarly,
FDG-PET imaging with FDG corresponds with histological
response to chemotherapy and survival in breast cancer
[56,57] .
We have been cautious in our interpretation of the current
data because of certain obvious limitations. Firstly, though
tumor cell lines and xenografts are well accepted and
important experimental model systems, they clearly do not
mimic natural tumors exactly. For example, the doubling
times for tumor cells lines in culture and used to produce
xenograft models exhibit much greater doubling times than
natural human malignancies. Also, there are significant
differences in the stromal bed and blood supply. It has been
previously noted and has been confirmed in the current
experiment that the SUVs are much lower in tumor xenograft
models than in cancers seen in patients. Nevertheless,
tumor cell lines and xenografts are invaluable in the study of
biology of tumors. Furthermore, tumor blood flow measure-
ments were not performed in this study and therefore, the
contribution of varying blood flow in different tumor types to
tumor FDG accumulation cannot be determined.
Our study is an experimental confirmation of a correlation
between FDG metabolism and tumor proliferative rates and
suggests that the FDG-PET may be useful in determination
of tumor prognosis and possibly even sensitivity to adjuvant
therapies. This imaging modality may accomplish such
assessment in a non- invasive manner. These preclinical
data, along with the preliminary clinical observation avail-
able, strongly encourage clinical trials in diverse tumor types
examining the prognostic significance of tumor FDG accu-
mulation as imaged by whole-body PET scanning.
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